SG11201407837WA - Beta-hairpin peptidomimetics - Google Patents
Beta-hairpin peptidomimeticsInfo
- Publication number
- SG11201407837WA SG11201407837WA SG11201407837WA SG11201407837WA SG11201407837WA SG 11201407837W A SG11201407837W A SG 11201407837WA SG 11201407837W A SG11201407837W A SG 11201407837WA SG 11201407837W A SG11201407837W A SG 11201407837WA SG 11201407837W A SG11201407837W A SG 11201407837WA
- Authority
- SG
- Singapore
- Prior art keywords
- xaa
- international
- cys
- basel
- tyr
- Prior art date
Links
- 239000000816 peptidomimetic Substances 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108010061299 CXCR4 Receptors Proteins 0.000 abstract 2
- 102000012000 CXCR4 Receptors Human genes 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- DSTWKJOBKSMVCV-UWVGGRQHSA-N Cys-Tyr Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DSTWKJOBKSMVCV-UWVGGRQHSA-N 0.000 abstract 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000006113 Zimmermann reaction Methods 0.000 abstract 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 238000002617 apheresis Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 108010069495 cysteinyltyrosine Proteins 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000017423 tissue regeneration Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/060766 WO2013182240A1 (en) | 2012-06-06 | 2012-06-06 | Beta-hairpin peptidomimetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407837WA true SG11201407837WA (en) | 2014-12-30 |
Family
ID=46208596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407837WA SG11201407837WA (en) | 2012-06-06 | 2012-06-06 | Beta-hairpin peptidomimetics |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9617308B2 (enExample) |
| EP (1) | EP2859012B1 (enExample) |
| JP (1) | JP6047231B2 (enExample) |
| CN (1) | CN104603145B (enExample) |
| AU (1) | AU2012381808B2 (enExample) |
| CA (1) | CA2875733C (enExample) |
| ES (1) | ES2647076T3 (enExample) |
| IL (1) | IL235946B (enExample) |
| IN (1) | IN2014KN02752A (enExample) |
| MX (1) | MX355396B (enExample) |
| SG (1) | SG11201407837WA (enExample) |
| WO (1) | WO2013182240A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0721259C1 (pt) | 2007-02-28 | 2021-05-25 | Polyphor Ltd | composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto |
| WO2013182240A1 (en) * | 2012-06-06 | 2013-12-12 | Polyphor Ag | Beta-hairpin peptidomimetics |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| MX380553B (es) | 2014-09-11 | 2025-03-12 | Bristol Myers Squibb Co | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| EA038019B1 (ru) | 2016-05-19 | 2021-06-23 | Бристол-Маерс Сквибб Компани | Иммуномодуляторы для пэт-визуализации |
| CN109922818B (zh) * | 2016-09-06 | 2024-02-20 | 主线生物科学公司 | Cxcr4拮抗剂及使用方法 |
| WO2018085750A2 (en) | 2016-11-07 | 2018-05-11 | Bristol-Myers Squibb Company | Immunomodulators |
| US11066445B2 (en) | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
| US11123437B2 (en) | 2017-09-05 | 2021-09-21 | Mainline Biosciences, Inc. | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
| CA3065086A1 (en) * | 2017-09-05 | 2019-03-14 | Mainline Biosciences | High affinity cxcr4 selective binding conjugate and method for using the same |
| JP7257393B2 (ja) | 2017-10-03 | 2023-04-13 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤 |
| JP2023510737A (ja) | 2020-01-06 | 2023-03-15 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤 |
| WO2021150258A1 (en) * | 2020-01-26 | 2021-07-29 | Mainline Biosciences Llc | Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same |
| KR20220161407A (ko) | 2020-03-30 | 2022-12-06 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| KR20230129388A (ko) | 2020-11-19 | 2023-09-08 | 스펙시스 아게 | 암 치료를 위한 펩타이드 cxcr4 억제제 및 탁산을 포함하는 약제학적 조합물 |
| WO2022184320A2 (en) | 2021-03-03 | 2022-09-09 | Spexis Ag | Medical use of cyclic peptides |
| WO2023285677A1 (en) | 2021-07-16 | 2023-01-19 | Spexis Ag | Pharmaceutical combinations for treating cancer |
| WO2023285681A1 (en) | 2021-07-16 | 2023-01-19 | Spexis Ag | Pharmaceutical combinations for treating cancer |
| WO2025068346A1 (en) | 2023-09-27 | 2025-04-03 | Spexis Ag | Pharmaceutical combination of cxcr4, pd-1 and fak inhibitors for treating cancer |
| WO2025068348A1 (en) | 2023-09-27 | 2025-04-03 | Spexis Ag | Pharmaceutical combination of cxcr4 and pd-1 inhibitors for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212288A (en) * | 1990-02-20 | 1993-05-18 | Syntex (U.S.A.) Inc. | Temporary minimal protection synthesis of serine-containing polypeptides |
| WO2004096839A1 (en) * | 2003-05-02 | 2004-11-11 | Polyphor Ag | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
| US8628750B2 (en) * | 2006-02-27 | 2014-01-14 | Technische Universitat Munchen | Cancer imaging and treatment |
| BRPI0721259C1 (pt) * | 2007-02-28 | 2021-05-25 | Polyphor Ltd | composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto |
| US8865656B2 (en) * | 2009-05-07 | 2014-10-21 | Polyphor Ag | Beta-hairpin peptidomimetics having CXCR4 antagonizing activity |
| US8716242B2 (en) * | 2009-12-04 | 2014-05-06 | Polyphor Ag | β-hairpin peptidomimetics |
| CA2838037C (en) * | 2011-06-07 | 2019-09-17 | Polyphor Ag | Beta-hairpin peptidomimetics as cxc4 antagonists |
| WO2013182240A1 (en) * | 2012-06-06 | 2013-12-12 | Polyphor Ag | Beta-hairpin peptidomimetics |
-
2012
- 2012-06-06 WO PCT/EP2012/060766 patent/WO2013182240A1/en not_active Ceased
- 2012-06-06 IN IN2752KON2014 patent/IN2014KN02752A/en unknown
- 2012-06-06 EP EP12725830.9A patent/EP2859012B1/en active Active
- 2012-06-06 AU AU2012381808A patent/AU2012381808B2/en not_active Ceased
- 2012-06-06 SG SG11201407837WA patent/SG11201407837WA/en unknown
- 2012-06-06 CN CN201280074311.1A patent/CN104603145B/zh not_active Expired - Fee Related
- 2012-06-06 JP JP2015515399A patent/JP6047231B2/ja not_active Expired - Fee Related
- 2012-06-06 US US14/406,108 patent/US9617308B2/en not_active Expired - Fee Related
- 2012-06-06 MX MX2014014840A patent/MX355396B/es active IP Right Grant
- 2012-06-06 ES ES12725830.9T patent/ES2647076T3/es active Active
- 2012-06-06 CA CA2875733A patent/CA2875733C/en active Active
-
2014
- 2014-11-27 IL IL235946A patent/IL235946B/en active IP Right Grant
-
2017
- 2017-02-27 US US15/444,045 patent/US10363284B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL235946B (en) | 2019-06-30 |
| CN104603145A (zh) | 2015-05-06 |
| CN104603145B (zh) | 2018-05-18 |
| AU2012381808A1 (en) | 2015-01-22 |
| MX2014014840A (es) | 2015-02-12 |
| HK1207867A1 (en) | 2016-02-12 |
| US20170165319A1 (en) | 2017-06-15 |
| EP2859012B1 (en) | 2017-08-09 |
| JP2015521204A (ja) | 2015-07-27 |
| US20150218219A1 (en) | 2015-08-06 |
| CA2875733C (en) | 2019-09-10 |
| US10363284B2 (en) | 2019-07-30 |
| JP6047231B2 (ja) | 2016-12-21 |
| IL235946A0 (en) | 2015-01-29 |
| AU2012381808B2 (en) | 2017-04-27 |
| EP2859012A1 (en) | 2015-04-15 |
| WO2013182240A1 (en) | 2013-12-12 |
| MX355396B (es) | 2018-04-18 |
| IN2014KN02752A (enExample) | 2015-05-08 |
| ES2647076T3 (es) | 2017-12-19 |
| NZ702470A (en) | 2016-12-23 |
| CA2875733A1 (en) | 2013-12-12 |
| US9617308B2 (en) | 2017-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407837WA (en) | Beta-hairpin peptidomimetics | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201806542PA (en) | Anti-mica antibodies | |
| SG11201809132RA (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201807185UA (en) | Modified hyaluronic acid, method for making same and uses thereof | |
| SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201907207UA (en) | Pharmaceutical combinations comprising an anti-ly75 antibody | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201407110QA (en) | Novel dosage form and formulation of abediterol | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900074WA (en) | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof | |
| SG11201809799WA (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions |